ENDP stock: buy or sell?

ENDP stock price: $3.48 3.57% At close on September 20th, 2019

Updated on:
September 20th, 2019


After sliding a spooky -14.88% yesterday, Endo International closed today at $3.48 and skyrocketed a great 3.57%. On Monday ENDP rocketed an amazing 7.62%.

Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets.

Should I buy ENDP stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Endo International stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean ENDP will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Endo International stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we detected 13 ratings published for ENDP stock in the last 30 days.

Is ENDP a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-8Royal Bank of Canadan/aHold
2019-7-15Morgan StanleyEqual WeightUnderweight
2019-7-11Royal Bank of CanadaOutperformSector Perform
2019-6-12Cantor Fitzgeraldn/aNeutral
2019-6-11Barclaysn/aEqual Weight
2019-5-13JPMorgan Chase & Co.NeutralUnderweight
2019-3-5Svb LeerinkOutperformMarket Perform
2019-3-5Leerink SwannOutperformMarket Perform
2019-3-19SunTrust Banksn/aBuy
2019-3-18JPMorgan Chase & Co.NeutralNeutral

ENDP stock analysis

Daily outlook

After sliding a spooky -14.88% yesterday, Endo International closed today at $3.48 and skyrocketed a great 3.57%.

After sliding a spooky -14.88% yesterday, Endo International closed today at $3.48 and skyrocketed a great 3.57%. ENDP is retaking the upward trend marking a new rising bottom heading to break out over $4.46. On Sep/10 ENDP price bounced up over the SMA of 50 days demonstrating to be a significant support for this stock.

ENDP stock chart (daily)

Weekly outlook

After boosting an amazing 10.05% in a week last week, Endo International closed this week at $3.48 and collapsed a spooky -10.31%.

Since price and 40-weeks moving average lines crossed down by mid December 2018, ENDP fell $-8.09 per share (-69.92%). Stocks below the 40-weeks moving average line are usually not recommended for average traders.

ENDP stock chart (weekly)

ENDP stock price history

ENDP IPO was on July 18th, 2000 at $14.50 per share1. Since then, ENDP stock lost a -76.00%, with a yearly average of -4.00%.

1: Adjusted price after possible price splits or reverse-splits.

ENDP stock historical price chart

ENDP stock reached 52-week highs on October at $18.50, and all-time highs 2015-04-16 with a price of 96.58.

ENDP stock price target is $6.20

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' ENDP stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we found 10 price targets for ENDP stock:
ENDP stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-8Royal Bank of CanadaReiteratesn/a$6.00-
2019-7-15Morgan StanleyDowngrades$8.00$3.00-62.5%
2019-7-11Royal Bank of CanadaDowngrades$11.00$6.00-45.5%
2019-6-12Cantor FitzgeraldReiterates$18.00$4.75-73.6%
2019-5-13JPMorgan Chase & Co.Downgradesn/a$9.00-
2019-3-18JPMorgan Chase & Co.Lowers Target$16.00$10.00-37.5%
(in average)$14.40$6.20-57.0%
Moving in a range from $10.00 and $3.00, the price forecast for Endo International stock is $6.20. In average, analysts' outlook on ENDP price forecast is negative, reducing the prediction by a -57.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, Endo International reported its latest financial data, posting an astounding climb for the Earnings per Share (EPS) ratio. Analyst expected $0.59 per share, but Endo International posted $0.75.
ENDP earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Endo International annual turnover plunged a frightening -15.04% to $2,947.08 M dollars from $3,468.86 marked in 2017. When comparing 2018 vs 2017, in contrary, profit margin (that is, the net income divided by revenues) boosted a 23.68% to -35.00%.

ENDP annual Sales and Income evolution
2013$2,620 M-$-535.50 M-20.4%-
2014$2,877 M9.82%$-721.32 M-25.1%34.70%
2015$3,269 M13.61%$-1,495.04 M-45.7%107.26%
2016$4,010 M22.69%$-3,347.07 M-83.5%123.88%
2017$3,469 M-13.50%$-2,035.43 M-58.7%-39.19%
2018$2,947 M-15.04%$-1,031.47 M-35.0%-49.32%

Quarterly financial results

Endo International reported $786.39 M in revenues for 2018-Q4, a 5.49% improvement compared to previous quarter. Reported quarter income marked $-291.91 million with a profit margin of -37.12%. Profit margin collapsed a -13.89% compared to previous quarter when profit margin was -23.23%. When comparing revenues to same quarter last year, Endo International sales marked a tiny growth and raised a 2.31%. Looking back to recent quarterly results, Endo International posted 3 negative quarters in a row.
ENDP quarterly Sales and Income evolution
2017-Q1$1,040 M-$-165.42 M-15.9%-
2017-Q2$876 M-15.80%$-696.02 M-79.5%320.76%
2017-Q3$787 M-10.15%$-96.67 M-12.3%-86.11%
2017-Q4$769 M-2.32%$-368.42 M-47.9%281.11%
2018-Q1$701 M-8.86%$-505.49 M-72.2%37.21%
2018-Q2$715 M2.02%$-60.87 M-8.5%-87.96%
2018-Q3$745 M4.31%$-173.21 M-23.2%184.56%
2018-Q4$786 M5.49%$-291.91 M-37.1%68.53%

Endo International ownership

When you are planning to buy shares of a company, it's always worth to review its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Endo International, 0.21% of all outstanding shares are owned by its staff.

Bearish positions for ENDP stock account 0.00%, no big difference from last month.

For a better understanding, the next table shows ownership data compared to other related stocks:

Market cap$787.8 M$419.8 M$1.1 B$364.7 M$205.0 M
Total shares226.4 M89.5 M46.6 M191.9 M84.0 M
Float shares176.5 M68.9 M42.1 M166.6 M83.1 M
  - Institutional holdings (%)96.7%58.8%62.4%46.1%113.9%
  - Insider holdings (%)0.2%6.0%2.9%4.0%2.2%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

ENDP summary

Friday, September 20th, 2019
Day range$3.33 - $3.67
Previous close$3.36
Session gain3.57%
Average true range$0.53
50d mov avg$3.05
100d mov avg$4.23
200d mov avg$6.65
Daily patternlb02a
Weekly pattern lt03a

Endo International performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared Endo International against BioDelivery Sciences International, Cara Therapeutics, DURECT, Mallinckrodt and Zogenix in the following table:
ENDPEndo Internationa...-9.38%-58.22%-78.41%
BDSIBioDelivery Scien...6.59%-8.22%64.56%
CARACara Therapeutics11.14%25.36%-1.04%

Endo International competitors

One check before trading any stock is to have a look a list of its competitors, in this case for Endo International. We picked 5 companies as Endo International competitors as they are in the same industry or have similar market objectives.